FDA Approved Monthly Subcutaneous Medicine For Schizophrenia

The U.S. Food and Drug Administration (FDA) recently approved PERSERIS, Indivior’s subcutaneous (applied under the skin), long-acting injectable for the treatment of schizophrenia. While the drug achieved clinically relevant levels after its first injection, PERSERIS is not intended to serve as a preventive vaccine.

Contained in PERSERIS is risperidone, an antipsychotic medication known for its efficacy in treating schizophrenia, bipolar disorder, and irritability in individuals with autism. The treatment is a once-monthly injection, meaning that it provides sustained levels of risperidone over the entirety of a month. The drug’s trial included a phase 3 randomized . . .